Which Analysts Are Watching Cel-Sci Corporation (CVM)?

(NASDAQ:JUNO) are making a strong comeback as they have jumped 49.6% since bottoming out at $17.52 on December 22, 2016. Over the trailing year, the stock is underperforming the S&P 500 by 98.03, and it's gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. The stock, after opening at $0.072, touched a high of $0.0884 before paring much of its gains.

Is It Worth the Risk? The average analysts gave this company a mean recommendation of 2.90. What do this target means? It helps investors in determining whether buying, selling or holding on to a stock would be beneficial for them. Sometimes it may seem like it, but analysts don't just pull their price targets out of thin air. The company's average Piotroski F-Score: 2 during the last 7 years.

JUNO's revenue has declined at an average annualized rate of about 0% during the past five years.

CEL-SCI Corporation (NYSE MKT: CVM) reported that it has responded to the U.S. Food and Drug Administration's (FDA) most recent communication from May 2017 about the clinical hold imposed on the Company's Phase 3 head and neck cancer study with Multikine* (Leukocyte Interleukin, Inj.). Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Beta can be useful to gauge stock price volatility in relation to the broader market. However it has a net margin of 14.50%.

The share price of Cel-Sci Corporation (CVM) was up +29.35% during the last trading session, with a day high of 0.12. It is now trading 0.45% off that level. Meanwhile, due to a recent pullback which led to a fall of nearly -26.91% in the past one month, the stock price is now outperforming with 19.64% so far on the year - still in strong zone.

"If the FDA finds the revisions made to the two documents to be satisfactory, Cel-Sci is hopeful that all of the clinical hold issues have now been addressed, and the FDA will consider lifting the clinical hold", the company said in a press release.

The good news is there's still room for the share price to grow. A recommendation of 1 or 2 would represent a consensus Buy.

The Average True Range indicator applied to a daily chart of Apple has a current ATR reading of 0.01.

The market capitalization of CEL-SCI Corporation is at $23.66 Million. Sure, the percentage is encouraging but more headwinds are coming as looking out over a next 5-year period, analysts expect the company to see its earnings go down by 0%, annually.

  • Zachary Reyes